LaMattina: R&D is a big challenge for small, big pharma alike

11/5/2013 | Forbes

Drug research and development is a highly challenging business for both big and small drugmakers, John LaMattina writes. Size makes little difference in terms of drug novelty or success, he writes. Not only giants like Pfizer and Merck but also small companies like Vertex are vulnerable to setbacks in their pipelines or among their approved drugs, he writes.

View Full Article in:

Forbes